TABLE 2.
Patient Number |
Age (y) | Sex | EN | Diagnosis | Serum Anti-HCV |
HCV-NS3 Protein |
---|---|---|---|---|---|---|
1 | 68 | M | No | SLL | + | − |
2 | 39 | M | No | DLBCL | + | − |
3 | 50 | M | No | FL | + | − |
4 | 57 | F | No | DLBCL | + | − |
5 | 71 | M | Yes | DLBCL | + | − |
6 | 51 | M | Yes | DLBCL | + | − |
7 | 41 | M | No | DLBCL | + | − |
8 | 56 | F | No | TCRLBL | + | − |
9 | 51 | F | Yes | DLBCL | + | − |
10 | 69 | M | No | DLBCL | − | − |
11 | 30 | M | No | DLBCL | + | − |
12 | 58 | F | No | DLBCL | + | − |
13 | 68 | M | No | DLBCL | + | − |
14 | 27 | M | No | DLBCL | + | − |
15 | 60 | F | No | DLBCL | + | + |
16 | 52 | F | No | TCRLBL | + | − |
17 | 34 | F | Yes | DLBCL | + | + |
18 | 48 | M | No | DLBCL | + | − |
19 | 52 | F | No | DLBCL | + | − |
20 | 72 | M | No | DLBCL | + | − |
21 | 38 | M | Yes | FL | + | − |
22 | 40 | M | No | DLBCL | + | − |
23 | 56 | F | No | DLBCL | + | − |
24 | 62 | M | No | SLL | + | + |
25 | 51 | M | Yes | DLBCL | + | + |
26 | 53 | F | No | MZL | + | − |
27 | 68 | M | No | FL | + | − |
28 | 53 | M | No | DLBCL | + | + |
29 | 68 | F | No | DLBCL | + | + |
30 | 53 | F | No | FL | + | − |
31 | 51 | F | No | DLBCL | + | − |
32 | 63 | M | No | DLBCL | + | − |
33 | 59 | F | Yes | DLBCL | + | − |
34 | 74 | M | No | FL | + | − |
35 | 48 | F | No | FL | + | + |
36 | 55 | M | No | FL | + | − |
37 | 61 | F | No | SLL | + | − |
38 | 55 | F | No | DLBCL | + | + |
39 | 41 | M | No | DLBCL | + | − |
DLBCL indicates diffuse large B-cell lymphoma; EN, extranodal presentation; F, female; FL, follicular lymphoma; HCV, hepatitis C virus; M, male; MZL, marginal zone lymphoma; SLL, small lymphocytic lymphoma; TCRLBL, T-cell rich large B-cell lymphoma.